Turkish guidelines for follow-on biologicals

INICIO/Directrices | Posted 27/04/2012 post-comment0 Post your comment

Last update:  23 July 2024

The regulatory body for approval of medicines in Turkey is the General Directorate of Pharmaceuticals and Pharmacy (GDPP). The agency is responsible, under the authority of the Ministry of Health of the Turkish Government, for the registration, marketing approval/authorisation, pricing of pharmaceuticals, legal classification, control of advertisement for pharmaceutical products as well as inspection of pharmaceutical manufacturers, wholesalers and retail pharmacies. The agency is assisted in its tasks by a number of expert committees.

picture 73

The legal basis for the pharmaceutical sector in Turkey is the Act on Medicinal Products for Human Use from 1928, which has been updated via various amendments.

Ministry of Health regulations stipulate that product registration can only be granted to a firm registered in Turkey. Thus, any pharmaceutical product imported into Turkey should be registered in the name of a Turkish agent or a Turkish commercial entity. Prior registration by a competent authority such as the European Medicines Agency or U.S. Food and Drug Administration facilitates Turkish registration but is not a prerequisite [1].

GDPP has the following guideline regarding biosimilars:

Overarching Guideline
This guideline covers all  follow-on biological products

Follow-on biological medicinal products guide
Effective date: August 2008
www.iegm.gov.tr/Folders/TheLaws/Biobenzer_Kilavuzu,07.08.2008,Eng._4621062.pdf

Turkey does not have any product-specific guidelines. The overarching guideline above refers to EMA guidelines for information regarding specific product types, e.g. G-CSF, epoetin.

Related article
EU guidelines for biosimilars

Source: GDPP, WHO

comment icon Comments (0)
Post your comment
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010